AZNAstraZenecaRunning, no new patients
Savolitinib vs. Sunitinib in MET-driven PRCC.
Carcinoma · Carcinoma, Renal Cell · Kidney Neoplasms · Urologic Neoplasms · Kidney Diseases · Neoplasms by Site · Enzyme Inhibitors · Protein Kinase Inhibitors
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 60 (final count)
- Started
- Jul 25, 2017
- Main results expected
- Aug 18, 2019
- Fully finished
- Dec 31, 2026
- Results posted
- Jul 10, 2020
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
Measured over: RECIST tumour assessments every 6 weeks from randomisation until disease progression as defined by Recist 1.1 and confirmed by BICR.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03091192 · record last updated 2026-07-14 · checked 2026-11-09 15:47 UTC